Close this search box.

Changes to Biosecure Act create breathing room for U.S. biotechs

ARTICLE | Politics, Policy & Law

Impact of the bill, which targets Chinese CDMOs, on Medicare and Medicaid reimbursement is unclear

By Steve Usdin, Washington Editor

May 11, 2024 1:01 AM UTC

Revisions to the Biosecure Act released Thursday evening provide breathing space for U.S. biopharma companies to transition away from Chinese contract manufacturing and development organizations.

Republican lawmakers, seeking to avoid parliamentary detours that would have slowed a House vote on the bill, backed away from plans to explicitly apply the bill to Medicare and Medicaid reimbursement. They may have substantially narrowed its scope, but this may not be clear until after it is enacted and implementation guidance is drafted.